Mozart Therapeutics, Inc. Email Format

Biotechnology ResearchWashington, United States11-50 Employees

Mozart Therapeutics, Inc. is a small, clinical-stage biotechnology company based in Seattle, Washington. It develops disease-modifying therapies for autoimmune diseases with the aim of restoring healthy immune system function. The company’s approach centers on modulators of CD8 regulatory T cells intended to address immune surveillance dysregulation and promote durable immune homeostasis across autoimmune conditions.

Its customers are patients affected by autoimmune diseases and the clinicians who treat them, seeking therapies that modify disease progression by reestablishing immune balance. In April 2026, Mozart Therapeutics reported interim Phase Ib results for MTX-101 in adults with Stage 3 type 1 diabetes, presented at the Immunology of Diabetes Society Congress, showing selective activation of CD8 regulatory T cells and reductions in pathogenic T cell populations, with higher-dose data indicating stable or improved C-peptide through about 20 weeks.

Sign up for free to view info

Company overview Employee directory